Top Abstract Purchase Related
Home
>
Node
>
Subnode

Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative

Kaiser, B.; Hauptmann, J.; Markwardt, F.

Folia Haematologica 115(1-2): 119-125

1988

ISSN/ISBN: 0323-4347
PMID: 2459005
Document Number: 317232
Antithrombotic, haemorrhagic and anticoagulant effects of unfractionated heparin (UH) and the low molecular weight heparin fragment KABI 2165 were studied in rats. In stasis-induced venous thrombosis of the jugular vein intravenous injection of both, UH and KABI 2165, either reduced significantly the size of thrombi or completely prevented thrombus formation in a dose-dependent manner. The dose of KABI 2165 required for prevention of thrombus formation showed a marked anticoagulant activity measured by APTT which was in the same range as that of the equieffective dose of UH. After administration of antithrombotically effective doses only UH caused a significant prolongation of bleeding time after standardized incision of the tail. KABI 2165 produced haemorrhagic effects at about 4-fold higher doses only than those required for the antithrombotic action.

Document emailed within 1 workday
Secure & encrypted payments

Kaiser, B.; Kühnemuth, G.; Markwardt, F. 1990: Pharmacological studies on the low molecular weight heparin derivative CY 216 Die Pharmazie 45(7): 522-524
Malinowska, K.; Iqbal, O.; Hoppensteadt, D.A.; Walenga, J.M.; Fareed, J. 1993: In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723 Seminars in Thrombosis and Hemostasis 19(Suppl 1): 58-62
Holst, J.; Lindblad, B.; Matthíasson, S.E.; Stjernquist, U.; Ezban, M.; Ostergaard, P.B.; Hedner, U. 1996: Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin Thrombosis and Haemostasis 75(4): 585-589
Petralia, P.; Kakkar, A.K. 2004: Antithrombotic therapy with low molecular weight heparin in cancer patients European Journal of Medical Research 9(3): 119-124
Tapparelli, C.; Metternich, R.; Gfeller, P.; Gafner, B.; Powling, M. 1995: Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin Thrombosis and Haemostasis 73(4): 641-647
Barrowcliffe, T.W.; Thomas, D.P. 1988: Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization Acta Chirurgica Scandinavica. Supplementum 543: 57-64
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125
Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294
Mätzsch, T.; Bergqvist, D.; Blomquist, P.; Jiborn, H. 1987: Influence of standard heparin or low molecular weight heparin on healing of abdominal wounds and colonic anastomoses in rats Acta Chirurgica Scandinavica 153(10): 593-598
Mousa, S.A.; Fareed, J. 2001: Overview: from heparin to low molecular weight heparin: beyond anticoagulation Current Opinion in Investigational Drugs 2(8): 1077-1080